Literature DB >> 194665

Carcinoembryonic antigen in cancer of the female reproductive system. Serial plasma values correlated with disease state.

P J DiSaia, C P Morrow, B J Haverback, B J Dyce.   

Abstract

The results of plasma carcinoembryonic antigen (CEA) determinations done over 600 patients with gynecologic malignancy will be presented. It would appear from this extensive survey that the likelihood of a patient having a positive value is increased with advancing stage and bulk of disease. The incidence of positive values in patients with clinical recurrence is quite impressive and presents a possible mode of follow-up for patients after standard treatment techniques have been administered for cervical cancer. Most interesting is the effect of radiation therapy or surgery on squamous cell cancer of the cervix and vulva in patients who have a positive value of the onset. Treatment of the disease by either modality appears to be associated with a precipitous drop in plasma value of CEA. Unfortunately, the presence or absence of CEA is not reliable and to date it is impossible to predict which patients with gynecologic malignancy will manifest a positive plasma value. Comments will be made concerning retro-de-differentiation and de-repression as a mechanism for the production of this antigen in patients with gynecologic cancer.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 194665     DOI: 10.1002/1097-0142(197706)39:6<2365::aid-cncr2820390609>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Use of carcinoembryonic antigen in follow-up of patients with ovarian cancer.

Authors:  M Koch; T A McPherson; A A Starreveld
Journal:  Can Med Assoc J       Date:  1980-11-08       Impact factor: 8.262

2.  Clinical significance of measurements of carcinoembryonic antigen in serum of patients with carcinoma of the uterine cervix.

Authors:  P Braun; G Hildenbrand; J Izbicki; G Leyendecker
Journal:  Arch Gynecol       Date:  1981

3.  Products of gynaecological neoplasms: clinical and pathological applications.

Authors:  A M Neville
Journal:  Arch Gynecol       Date:  1980

Review 4.  Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.

Authors:  Jill K Alldredge; Krishnansu S Tewari
Journal:  Oncologist       Date:  2016-03-29

5.  Measurement of urinary beta core fragment of human chorionic gonadotrophin in women with vulvovaginal malignancy and its prognostic significance.

Authors:  P G Carter; R K Iles; P Neven; T E Ind; J H Shepherd; T Chard
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

6.  Ability of CEA blood levels to reflect tumour burden: a study in a human xenograft model.

Authors:  J B Quayle
Journal:  Br J Cancer       Date:  1982-08       Impact factor: 7.640

7.  Oncofoetal antigens in cancer of the cervix and ovary.

Authors:  M N Cauchi; S H Koh; D Lim; D L Hay
Journal:  Br J Cancer       Date:  1981-09       Impact factor: 7.640

8.  Discovery and validation of novel biomarkers for detection of cervical cancer.

Authors:  Zigang Li; Jianhua Chen; Shaobo Zhao; Yajun Li; Jie Zhou; Jianghong Liang; Huifang Tang
Journal:  Cancer Med       Date:  2021-02-23       Impact factor: 4.452

9.  Diagnostic significance of a color Doppler ultrasound combined with serum CXCL16 and E-cad in cervical cancer.

Authors:  Wenrong Wang; Xing Gao; Yuan Zhu; Yaozhi Qi; Yanjuan Wang
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.